report_lead_image_with_gradient.png
Q1 2024

Medtech Report

Download this Report
To download this report, please complete the form below

Fill out the form to download a preview of this report. The full report is available through the PitchBook Platform.

Medtech VCs stay active despite tough conditions
Medtech VC investment rebounded significantly to $3.3 billion in Q1 as investors piled into high-quality companies despite historically low deal volume, our Q1 2024 Medtech Report explains.

  • The largest deal went to early cancer detection startup Freenome, which raised a $254 million late-stage round led by Roche Venture Fund.
  • Public medtech valuations have stabilized, and there are pockets of rising valuations within medical devices, consumer health, and life sciences. But exits remain hard to come by.
  • The report dives into two areas of emerging opportunities—whole-body scans and cardiac arrest prevention and treatment—that investors should be watching.

Table of contents
Vertical update 3
Q1 2024 timeline 4
Medtech landscape 5
Medtech VC and PE ecosystem market map 6
VC and PE activity 7
Emerging opportunities 11
       Whole-body scans 12
       Cardiac arrest prevention and treatment 14
Select company highlights 16
       Healthy.io 17
       Paige AI 19
Appendix 21